Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.

Blood advances·2026
Same author

Axes of biological variation in diffuse large B cell lymphoma.

Cancer cell·2026
Same author

Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.

British journal of haematology·2025
Same author

Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma.

Cancers·2025
Same author

Delayed rebound intracranial hypertension following treatment for a spontaneous CSF leak in a patient with Marfan syndrome.

Acta neurologica Belgica·2025
Same author

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Jun 14, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Rituximab-associated neutropenia.

Kieron Dunleavy1, Kevin Tay, Wyndham H Wilson

  • 1Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Seminars in Hematology
|March 31, 2010
PubMed
Summary

Late-onset neutropenia can occur months after rituximab therapy. This condition is typically mild and resolves on its own, but awareness is crucial due to rituximab

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Recent studies highlight late-onset neutropenia (LON) following rituximab or rituximab-based therapies.
  • This adverse event typically manifests months after treatment initiation.
  • The expanding applications of rituximab in various disorders necessitate understanding its side effect profile.

Purpose of the Study:

  • To summarize the phenomenon of late-onset neutropenia after rituximab administration.
  • To emphasize the clinical significance and recognition of this side effect.
  • To discuss the biological intrigue and proposed hypotheses regarding its pathogenesis.

Main Methods:

  • Review of recent scientific literature.
  • Analysis of reported cases of late-onset neutropenia post-rituximab.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Jun 14, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

  • Synthesis of proposed pathogenetic mechanisms.

    • Main Results:

    • Late-onset neutropenia is a recognized complication of rituximab therapy.
    • The condition is generally self-limited and not clinically significant.
    • Occurrence is typically several months post-administration.

    Conclusions:

    • Clinicians should be aware of the potential for late-onset neutropenia.
    • While often benign, recognition is important given rituximab's widespread use.
    • Further research is needed to fully elucidate the underlying mechanisms of rituximab-induced late-onset neutropenia.